Session Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): E. Kahre (1), L. Galow (1), A. Dalpke (2), R. Berner (1), J. Armann (1)
Authors Affiliations(s): (1) 1. University Children's Hospital Technische Universität (TU), Germany, (2) Institute for Medical Microbiology and Virology, Medical Faculty Carl Gustav Carus, Technische Universität, Germany
Background:
Longitudinal studies on SARS-CoV-2 antibody kinetics comparing different commercially available assays are currently lacking.
Methods:Individuals with confirmed SARS-CoV-2 infections had their SARS-CoV-2 antibody status analyzed twice using three commercially avbailable antibody assays.
Diasorin LIAISON® SARS-CoV-2 S1/S2 IgG Assay, Abbott Diagnostics® ARCHITECT SARS-CoV-2 IgG and Euroimmun® Anti-SARS-CoV-2 ELISA were used.
Results:122 individuals were enrolled in this study. Median time between first SARS-CoV-2 antibody assessment and the infection was 144 days. 100 participants had detectable antibodies in the Diasorin LIAISON® assay, 96 in the Euroimmun® assay and 70 in the Abbott Diagnostics® Assay. 99 participants had detectable antibodies against SARS-CoV-2 in at least two different assays at baseline. Time between infection and antibody assessment (146 days/141 days), Hospitalization rate (8/99(8%)/0/23 (0%)) and frequency of reported symptoms (75/99 (76%)/ 17/23 (74%)) did not differ significantly between participants with at least one positive assay versus none. Seropositivity, however, differed significantly depending on test indication. While 44/50 (88%) participants with a defined SARS-CoV-2 positive contact were seropositive and 18/19 (95%) who were tested related to travel history only 18/32 (56%) were seropositive who were tested solely based on symptoms. Median time between second antibody assessment and infection was 295 days. 98/100 (98%) of participants with initially detectable antibodies in the Diasorin LIAISON® assay, 71/96 (74%) in the Euroimmun® assay and 21/70 (30%) in Abbott Diagnostics® continued to have detectable antibodies 9-11 months after the infection.
Conclusions:There are relevant differences in SARS-CoV-2 antibody kinetics comparing different assays that warrent further studies especially when using these assays is seroepidemiological studies.
Keyword(s): COVID19, Antibody kinetics, seroprevalenceCOI Institutional Grants: Yes
Session Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): E. Kahre (1), L. Galow (1), A. Dalpke (2), R. Berner (1), J. Armann (1)
Authors Affiliations(s): (1) 1. University Children's Hospital Technische Universität (TU), Germany, (2) Institute for Medical Microbiology and Virology, Medical Faculty Carl Gustav Carus, Technische Universität, Germany
Background:
Longitudinal studies on SARS-CoV-2 antibody kinetics comparing different commercially available assays are currently lacking.
Methods:Individuals with confirmed SARS-CoV-2 infections had their SARS-CoV-2 antibody status analyzed twice using three commercially avbailable antibody assays.
Diasorin LIAISON® SARS-CoV-2 S1/S2 IgG Assay, Abbott Diagnostics® ARCHITECT SARS-CoV-2 IgG and Euroimmun® Anti-SARS-CoV-2 ELISA were used.
Results:122 individuals were enrolled in this study. Median time between first SARS-CoV-2 antibody assessment and the infection was 144 days. 100 participants had detectable antibodies in the Diasorin LIAISON® assay, 96 in the Euroimmun® assay and 70 in the Abbott Diagnostics® Assay. 99 participants had detectable antibodies against SARS-CoV-2 in at least two different assays at baseline. Time between infection and antibody assessment (146 days/141 days), Hospitalization rate (8/99(8%)/0/23 (0%)) and frequency of reported symptoms (75/99 (76%)/ 17/23 (74%)) did not differ significantly between participants with at least one positive assay versus none. Seropositivity, however, differed significantly depending on test indication. While 44/50 (88%) participants with a defined SARS-CoV-2 positive contact were seropositive and 18/19 (95%) who were tested related to travel history only 18/32 (56%) were seropositive who were tested solely based on symptoms. Median time between second antibody assessment and infection was 295 days. 98/100 (98%) of participants with initially detectable antibodies in the Diasorin LIAISON® assay, 71/96 (74%) in the Euroimmun® assay and 21/70 (30%) in Abbott Diagnostics® continued to have detectable antibodies 9-11 months after the infection.
Conclusions:There are relevant differences in SARS-CoV-2 antibody kinetics comparing different assays that warrent further studies especially when using these assays is seroepidemiological studies.
Keyword(s): COVID19, Antibody kinetics, seroprevalenceCOI Institutional Grants: Yes